Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting

References

• American Psychiatric Association. DSM-5 task force. diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington D.C: American Psychiatric Association; 2013.
   Google Scholar
• Dydyk AM, Jain NK, Gupta M. Opioid use disorder. statPearls. Treasure Island (FL):StatPearls Publishing Copyright ©. 2021 StatPearls Publishing LLC.; 2021
   Google Scholar
• Sharma B, Bruner A, Barnett G, et al. Opioid use disorders. Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):473–487.
   PubMed Web of Science ®Google Scholar
• Bolshakova M, Bluthenthal R, Sussman S. Opioid use and misuse: health impact, prevalence, correlates and interventions. Psychol Health. 2019 09;34(9):1105–1139.
   PubMed Web of Science ®Google Scholar
• Wurcel AG, Merchant EA, Clark RP, et al. Emerging and Underrecognized Complications of Illicit Drug Use. Clin Infect Dis. 2015 Dec 15 61(12):1840–1849.
   PubMed Web of Science ®Google Scholar
• Weiss A, Elixhauser A, Barrett M, et al. Opioid-related inpatient stays and emergency department visits by state, 2009–2014: statistical Brief #219. AHRQ (US). 2016
   Google Scholar
• Peterson C, Xu L, Mikosz CA, et al. US hospital discharges documenting patient opioid use disorder without opioid overdose or treatment services, 2011-2015. J Subst Abuse Treat. 2018 09;92:35–39.
   PubMed Web of Science ®Google Scholar
• Nolan NS, Marks LR, Liang SY, et al. Medications for opioid use disorder associated with less against medical advice discharge among persons who inject drugs hospitalized with an invasive infection. J Addict Med. 2021 Apr 1 15(2):155–158.
   PubMed Web of Science ®Google Scholar
• Herscher M, Fine M, Navalurkar R, et al. Diagnosis and management of opioid use disorder in hospitalized patients. Med Clin North Am. 2020 [2020 July 01];104(4):695–708.
   PubMed Web of Science ®Google Scholar
• Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients. JAMA Intern Med. 2014 [2014 August 01];174(8):1369.
   PubMed Web of Science ®Google Scholar
• Bluthenthal RN, Simpson K, Ceasar RC, et al. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. Drug Alcohol Depend. 2020 Jun 1;211:107932.
   PubMed Web of Science ®Google Scholar
• Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med. 2019 May;73(5):481–487.
   PubMed Web of Science ®Google Scholar
• Varshneya NB, Thakrar AP, Hobelmann JG, et al. Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. J Addict Med. 2021 Nov 23; Publish Ahead of Print
   Web of Science ®Google Scholar
• AB S, Jj M, FR L. New directions in the treatment of opioid withdrawal. Lancet. 2020 [2020 June 01];395(10241):1938–1948.
   PubMed Web of Science ®Google Scholar
• DR W, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003 [2003 June 01];35(2):253–259.
   PubMed Web of Science ®Google Scholar
• SE W, MR L, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 2020 [2020 February 05];3(2):e1920622.
   PubMed Web of Science ®Google Scholar
• Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011 Sep;07(9):CD005031.
   Google Scholar
• Amato L, Davoli M, Ferri M, et al. Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend. 2004 Mar 08 73(3):219–226.
   PubMed Web of Science ®Google Scholar
• Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009 Aug;10(11):1727–1740.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Patkar AA, Peindl K, et al. Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. Addict Biol. 2009 Apr;14(2):204–213.
   PubMed Web of Science ®Google Scholar
• Peterson JA, Schwartz RP, Mitchell SG, et al. Why don’t out-of-treatment individuals enter methadone treatment programmes? Int J Drug Policy. 2010 Jan;21(1):36–42.
   PubMed Web of Science ®Google Scholar
• Donroe JH, Bhatraju EP, Tsui JI, et al. Identification and management of opioid use disorder in primary care: an update. Curr Psychiatry Rep. 2020 Apr 13 22(5):23.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009 Jul;08(3):CD002209.
   Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 Feb;6(2). Cd002207.
   Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 Apr 26;357:j1550.
   PubMedGoogle Scholar
• Lugo R, Satterfield K, and Kern S. Pharmacokinetics of methadone. J pain & palliative care pharmacotherapy. 2005;19(4):13–24.
   PubMedGoogle Scholar
• Noska A, Mohan A, Wakeman S, et al. Managing opioid use disorder during and after acute hospitalization: a case-based review clarifying methadone regulation for acute care settings. J BEHAV ADDICT. 2015;4(2).
   Google Scholar
• PJ J, Chadi N, Roy P, et al. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study. Drug Alcohol Depend. 2020 [2020 June 01];211:107968.
   PubMed Web of Science ®Google Scholar
• Trowbridge P, Weinstein ZM, Kerensky T, et al. Addiction consultation services - linking hospitalized patients to outpatient addiction treatment. J Subst Abuse Treat. 2017 Aug;79:1–5.
   PubMed Web of Science ®Google Scholar
• Titus-Lay EN, Jaynes HA, Tomaselli Muensterman E, et al. Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program. Pharmacotherapy. 2021 03; 41(3): 238–246.
   PubMed Web of Science ®Google Scholar
• Anchersen K, Clausen T, Gossop M, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009 Jun;104(6):993–999.
   PubMed Web of Science ®Google Scholar
• Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005 Nov;14(11):747–753.
   PubMed Web of Science ®Google Scholar
• Piguet V, Desmeules J, Ehret G, et al. QT interval prolongation in patients on methadone with concomitant drugs. J Clin Psychopharmacol. 2004 Aug;24(4):446–448.
   PubMed Web of Science ®Google Scholar
• American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020 March-April;14(2S Suppl 1):1–91.
   Google Scholar
• Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American pain society and college on problems of drug dependence, in collaboration with the heart rhythm society. J Pain. 2014 Apr;15(4):321–337.
   PubMed Web of Science ®Google Scholar
• Bromley L, Kahan M, and Regenstreif L, et al. Methadone treatment for people who use fentanyl: recommendations. META: PHI. 2021; [cited 2022 May 2]. Available from: https://www.metaphi.ca/wp-content/uploads/Guide_MethadoneForFentanyl.pdf
   Google Scholar
• DA V, Xu Y, CG S, et al. Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 [2018 December 01];107(12):2983–2991.
   PubMed Web of Science ®Google Scholar
• Baxter LE, Campbell A, Deshields M, et al. Safe methadone induction and stabilization: report of an expert panel. J Addict Med. 2013 Nov-Dec;7(6):377–386.
   PubMed Web of Science ®Google Scholar
• Hemmons P, Bach P, Colizza K, et al. Initiation and rapid titration of methadone in an acute care setting for the treatment of opioid use disorder: a case report. J Addict Med. 2019 September-October;13(5):408–411.
   PubMed Web of Science ®Google Scholar
• Fareed A, Casarella J, Roberts M, et al. High dose versus moderate dose methadone maintenance: is there a better outcome? J Addict Dis. 2009 Oct;28(4):399–405.
   PubMed Web of Science ®Google Scholar
• Strain EC, Bigelow GE, Liebson IA, et al. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999 Mar 17 281(11):1000–1005.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, et al. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993 Jul 01 119(1):23–27.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014 Feb 01 65(2):158–170.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994 May;55(5):569–580.
   PubMed Web of Science ®Google Scholar
• Harris SC, Morganroth J, Ripa SR, et al. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials. Postgrad Med. 2017 Jan;129(1):69–80.
   PubMed Web of Science ®Google Scholar
• Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019 March-April;13(2):93–103.
   PubMed Web of Science ®Google Scholar
• Zoorob R, Kowalchuk A, Mejia de Grubb M. Buprenorphine therapy for opioid use disorder. Am Fam Physician. 2018 Mar 01;97(5):313–320.
   PubMed Web of Science ®Google Scholar
• De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021 May;41(5):425–436.
   PubMed Web of Science ®Google Scholar
• Cisewski DH, Santos C, Koyfman A, et al. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting. Am J Emerg Med. 2019 01; 37(1): 143–150.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Bhivandkar S, Lonergan BB, et al. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict. 2021 07; 30(4): 305–315.
   PubMed Web of Science ®Google Scholar
• Button D, Hartley J, and Robbins J, et al. Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis. J Addict Med. 2022;16(2):e105–e111 .
   PubMed Web of Science ®Google Scholar
• Kolla BP, Oesterle T, Gold M, et al. Infectious diseases occurring in the context of substance use disorders: a concise review. J Neurol Sci. 2020 Apr 15;411:116719.
   PubMed Web of Science ®Google Scholar
• Sweeney S, Ward Z, Platt L, et al. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. Addiction. 2019 03; 114(3): 560–570.
   PubMed Web of Science ®Google Scholar
• Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997 Jun 21; 349(9068):1797–1800.
   PubMed Web of Science ®Google Scholar
• Wang QQ, Kaelber DC, Xu R, et al. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021 [2021 January 01];26(1):30–39.
   PubMed Web of Science ®Google Scholar
• Owens DK, Davidson KW, Krist AH, Force UPST. Preexposure prophylaxis for the prevention of HIV infection: US preventive services task force recommendation statement. JAMA. 2019;321(22):2203–2213.
   PubMed Web of Science ®Google Scholar
• Mars SG, Ondocsin J, Ciccarone D. Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency. Harm Reduct J. 2018 [2018 December 01]; 15(1).
   PubMedGoogle Scholar
• Taylor JL, Johnson S, Cruz R, et al. Integrating harm reduction into outpatient opioid use disorder treatment settings. J Gen Intern Med. 2021 [2021 December 01];36(12):3810–3819.
   PubMed Web of Science ®Google Scholar
• Grewal HK, Ti L, Hayashi K, et al. Illicit drug use in acute care settings. Drug Alcohol Rev. 2015 [2015 September 01];34(5):499–502.
   PubMed Web of Science ®Google Scholar
• Barnett BS, Morris NP, Suzuki J. Addressing in-hospital illicit substance use.Lancet Psychiatry. 2021 [2021 January 01];8(1):17–18.
   PubMed Web of Science ®Google Scholar
• Sharma M, Lamba W, Cauderella A, et al. Harm reduction in hospitals. Harm Reduct J. 2017 [2017 December 01];14(1).
   Google Scholar
• Shrestha NK, Shrestha J, Everett A, et al. Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study. J Antimicrob Chemother. 2016 [2016 February 01];71(2):506–512.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Johnson J, Montgomery M, et al. Outpatient parenteral antimicrobial therapy among people who inject drugs: a review of the literature. Open Forum Infect Dis. 2018 [2018 September 01];5(9).
   PubMed Web of Science ®Google Scholar
• Fanucchi L, Leedy N, Li J, et al. Perceptions and practices of physicians regarding outpatient parenteral antibiotic therapy in persons who inject drugs. J Hosp Med. 2016 [2016 August 01];11(8):581–582.
   PubMed Web of Science ®Google Scholar
• Norris AH, Shrestha NK, Allison GM, et al. Infectious diseases society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapya. Clinl Infect Dis. 2018;68(1):e1–e35. 2019 2019 January 01
   Google Scholar
• Fanucchi LC, Walsh SL, Thornton AC, et al. Integrated outpatient treatment of opioid use disorder and injection-related infections: a description of a new care model. Prev Med. 2019 Nov;128:105760.
   PubMed Web of Science ®Google Scholar
• Gonçalves-Bradley DC, Lannin NA, and Clemson LM, et al. Discharge planning from hospital. Cochrane database of systematic reviews. 2016;2016(1): CD000313.
   Google Scholar
• Merchant E, Burke D, Shaw L, et al. Hospitalization outcomes of people who use drugs: one size does not fit all. J Subst Abuse Treat. 2020 May;112:23–28.
   PubMed Web of Science ®Google Scholar
• Rowell-Cunsolo TL, Liu J, Hu G, et al. Length of hospitalization and hospital readmissions among patients with substance use disorders in New York City, NY USA. Drug Alcohol Depend. 2020 Jul 1;212:107987.
   PubMed Web of Science ®Google Scholar
• Roy PJ, Price R, Choi S, et al. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021 July 01;224:108703.
   PubMed Web of Science ®Google Scholar
• Strashny A. Services offered by outpatient-only opioid treatment programs: 2012. The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2013. p. 1–11.
   Google Scholar
• Langabeer JR, Gourishankar A, Chambers KA, et al. Disparities between US opioid overdose deaths and treatment capacity: a geospatial and descriptive analysis. J Addict Med. 2019 November-December;13(6):476–482.
   PubMed Web of Science ®Google Scholar
• Wen H, Borders TF, Cummings JR. Trends in buprenorphine prescribing by physician specialty. Health Aff (Millwood). 2019 Jan;38(1):24–28.
   PubMed Web of Science ®Google Scholar
• Meinhofer A, Witman AE. The role of health insurance on treatment for opioid use disorders: evidence from the affordable care act medicaid expansion. J Health Econ. 2018 07;60:177–197.
   PubMed Web of Science ®Google Scholar
• Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016 Dec 01; 169:117–127
   PubMed Web of Science ®Google Scholar